Last reviewed · How we verify
NCT05594953
Outcomes Using MARS for Patients With ALF
trial in Alcoholic Hepatitis in 30 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Methodist Health System |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 23 April 2021 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across United States |
Conditions studied
- Alcoholic Hepatitis — all drugs for Alcoholic Hepatitis →
- Acute Liver Failure — all drugs for Acute Liver Failure →
Sponsor
Methodist Health System — full company profile →
Who can join
Eligibility, any sex, with Alcoholic Hepatitis or Acute Liver Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Retrospective chart review will be conducted on patients at Methodist Dallas Medical Center, meeting the inclusion criteria from January 1, 2019 to December 15, 2020 to determine the transplant free survival and overall survival and other secondary outcome measures.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05594953
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alcoholic Hepatitis
Currently open trials in the same condition.
- NCT06919458 — Short Course Steroids in Alcohol Associated Hepatitis · Phase 3 · recruiting
- NCT06307964 — Intra-Hepatic Microbiota in Alcoholic Hepatitis · recruiting
- NCT05006430 — Safety Evaluation of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis · Phase 1, PHASE2 · recruiting
- NCT05018481 — HA35 Moderate Alcoholic Hepatitis (AH) Study · EARLY_PHASE1 · recruiting
- NCT02473341 — Gut-Liver Axis Modulation With IgG-Enriched Immunotherapy in Severe Alcohol-Associated Hepatitis · Phase 3 · active not recruiting
Other Methodist Health System trials
Trials by the same sponsor.
- NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
- NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
- NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
- NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
- NCT07492758 — Management of Extremity Injuries Registry · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05594953 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
- Last refreshed: 27 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05594953.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing